Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.

Abstract : INTRODUCTION: Methotrexate (MTX) has been shown to modify infliximab pharmacokinetics in rheumatoid arthritis. However, its combination with infliximab in the treatment of ankylosing spondylitis (AS) is not recommended. The objective of this study was to examine the influence of MTX on infliximab exposure in patients with AS. METHODS: Patients with AS patients who had predominantly axial symptoms were randomised to receive infliximab alone (infusions of 5 mg/kg at weeks 0, 2, 6, 12 and 18) or infliximab combined with MTX (10 mg/week). Infliximab concentrations were measured before and 2 hours after each infusion and at 1, 3, 4, 5, 8, 10, 14 and 18 weeks. We estimated individual cumulative area under the concentration versus time curves (AUC) for infliximab concentration between baseline and week 18 (AUC(0-18)). Clinical and laboratory evaluations were performed at each visit. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was the primary end point for clinical response. RESULTS: Twenty-six patients were included (infliximab group: n = 12, infliximab + MTX group: n = 14), and 507 serum samples were available for measurement of infliximab concentration. The two groups did not differ with regard to AUC(0-18) or evolution of BASDAI scores and biomarkers of inflammation. CONCLUSIONS: The combination of MTX and infliximab does not increase the exposure to infliximab over infliximab alone in patients with AS. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00507403.
Type de document :
Article dans une revue
Arthritis Research and Therapy, BioMed Central, 2011, 13 (3), pp.R82. 〈10.1186/ar3350〉
Liste complète des métadonnées

Littérature citée [20 références]  Voir  Masquer  Télécharger

https://hal-univ-tours.archives-ouvertes.fr/hal-00922332
Contributeur : Denis Mulleman <>
Soumis le : mercredi 25 décembre 2013 - 23:31:48
Dernière modification le : vendredi 22 juin 2018 - 17:08:05
Document(s) archivé(s) le : mardi 25 mars 2014 - 22:20:59

Fichier

Mulleman_AR_T_2011.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Denis Mulleman, Francine Lauféron, Daniel Wendling, David Ternant, Emilie Ducourau, et al.. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.. Arthritis Research and Therapy, BioMed Central, 2011, 13 (3), pp.R82. 〈10.1186/ar3350〉. 〈hal-00922332〉

Partager

Métriques

Consultations de la notice

434

Téléchargements de fichiers

186